Browsing by Author "Ademoglu, Esra Nur"

Now showing 1 - 2 of 2

The Effect of Disease Control on Mean Platelet Volume and Red Blood Cell Distribution in Patients With Acromegaly
(E-century Publishing Corp, 2015) Ucler, Rifki; Aslan, Mehmet; Atmaca, Murat; Alay, Murat; Ademoglu, Esra Nur; Candan, Zehra; Gulsen, Ismail
Objectives: Several studies have shown increased atherogenic risk factors and biomarkers of inflammation and atherosclerosis in association with growth hormone excess. Mean platelet volume (MPV) and red blood cell distribution (RDW) are currently gaining interest as new independent cardiovascular risk factors. The aim of this study was to evaluate the effect of disease control on MPV and RDW in acromegaly patients. Materials and methods: We retrospectively enrolled 36 acromegaly patients (23 males, 13 females; mean age 41.94 +/- 11.55). Patients were divided into two groups: disease controlled by surgical treatment alone (group A) or by somatostatin analog (SSA) therapy (group B). MPV and RDW measurements were evaluated during active and inactive disease periods in the two groups. Results: There were statistically significant increases in MPV and RDW in patients receiving SSA therapy (P = 0.012 and P = 0.020, respectively). The differences in MPV and RDW changes in patients receiving surgical treatment alone were not statistically significant (P=0.364 and P=0.339, respectively). Conclusions: This is the first report on the evaluated the effect of disease control on MPV and RDW in acromegaly patients. Our study results showed that MPV and RDW measurements are significantly increased in acromegaly patients with disease controlled by SSA therapy. Therefore, acromegalic patients treated with SSAs may have increased cardiovascular risk based on an increase in MPV and RDW.
Serum Nesfatin-1 Levels Are Decreased in Pregnant Women Newly Diagnosed With Gestational Diabetes
(Sbem-soc Brasil Endocrinologia & Metabologia, 2017) Ademoglu, Esra Nur; Gorar, Suheyla; Keskin, Muge; Carlioglu, Ayse; Ucler, Rifki; Erdamar, Husamettin; Aral, Yalcin
Objective: To investigate serum nesfatin-1 levels at 24-28 weeks of pregnancy in women newly diagnosed with gestational diabetes and determine the association of nesfatin-1 with several metabolic parameters. Subjects and methods: Forty women newly diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women matched in age and gestational week were included in this cross-sectional study. Serum nesfatin-1 levels were analyzed using ELISA, and the relationship between nesfatin-1 and several metabolic parameters were assessed. Results: Serum nesfatin-1 levels were found to be lower in women with gestational diabetes compared to the pregnant women in the control sample (p = 0.020). Multiple linear regression analysis revealed that nesfatin-1 was lower in participants with gestational diabetes independently from gestational age, BMI, HOMA-IR, fasting plasma glucose, and age. In correlation analysis, the only variable that was found to have a statistically significant correlation with nesfatin-1 was gestational age (p = 0.015, r = 0.30). Conclusion: Lower nesfatin-1 levels in women with gestational diabetes compared to the control group at 24-28 weeks of gestation draws attention to nesfatin-1 levels in gestational diabetes and motivates further research in this area.